You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

ICLUSIG Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Iclusig patents expire, and what generic alternatives are available?

Iclusig is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and four patent family members in twenty-three countries.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ponatinib hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Iclusig

Iclusig was eligible for patent challenges on December 14, 2016.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (ponatinib hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ICLUSIG?
  • What are the global sales for ICLUSIG?
  • What is Average Wholesale Price for ICLUSIG?
Drug patent expirations by year for ICLUSIG
Drug Prices for ICLUSIG

See drug prices for ICLUSIG

Recent Clinical Trials for ICLUSIG

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of ChicagoPhase 2
Institute of Hematology and Blood Transfusion, Czech RepublicPhase 2
CZECRIN - Czech Clinical Research Infrastructure NetworkPhase 2

See all ICLUSIG clinical trials

Pharmacology for ICLUSIG
Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Paragraph IV (Patent) Challenges for ICLUSIG
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ICLUSIG Tablets ponatinib hydrochloride 10 mg and 30 mg 203469 1 2022-12-12
ICLUSIG Tablets ponatinib hydrochloride 15 mg and 45 mg 203469 1 2021-03-31

US Patents and Regulatory Information for ICLUSIG

ICLUSIG is protected by seventeen US patents and two FDA Regulatory Exclusivities.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-003 Apr 23, 2015 RX Yes No ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-003 Apr 23, 2015 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-002 Dec 14, 2012 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-003 Apr 23, 2015 RX Yes No ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-002 Dec 14, 2012 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ICLUSIG

When does loss-of-exclusivity occur for ICLUSIG?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 13204506
Patent: Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
Estimated Expiration: ⤷  Subscribe

Patent: 16210725
Patent: Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
Estimated Expiration: ⤷  Subscribe

Patent: 18201013
Patent: Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
Estimated Expiration: ⤷  Subscribe

Patent: 19240721
Patent: Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
Estimated Expiration: ⤷  Subscribe

Patent: 21221493
Patent: Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
Estimated Expiration: ⤷  Subscribe

Patent: 23219845
Patent: Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N- {4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 15506
Patent: FORMES CRISTALLINES DE 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZ IN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE)
Estimated Expiration: ⤷  Subscribe

Patent: 22250
Patent: FORMES CRISTALLINES DE 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZ IN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE)
Estimated Expiration: ⤷  Subscribe

Patent: 67093
Patent: FORME CRISTALLINE C DU MONOCHLORHYDRATE DE BENZAMIDE A FONCTION 3-(IMIDAZO[1,2-B]PYRIDAZINE-3-YLETHYNYL)-4-METHYLE-N-{4-[(4-METHYLPIPERAZINE-1-YL)METHYLE)3(TRIFLUOROMETHYLE)PHENYLE} (CRYSTALLINE FORM C OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL)-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE)
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 15001643
Patent: Formas cristalinas de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y su sal monoclorhidrato; composicion farmaceutica que las comprende; proceso para preparar la forma cristalina a; y metodo para tratar leucemias seleccionadas de la cml o la ph+ aal.
Estimated Expiration: ⤷  Subscribe

China

Patent: 5188701
Patent: Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt
Estimated Expiration: ⤷  Subscribe

Patent: 5043843
Patent: 3-(咪唑并[1,2-B]哒嗪-3-基乙炔基)-4-甲基-N{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺和它的单盐酸盐的晶形 (Crystalline forms of 3-(imidazo [1, 2-b] pyridazin-3-ylethynyl)-4-methyl-n {4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl) phenyl} benzamide and its monohydrochloride)
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 18878
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 47508
Estimated Expiration: ⤷  Subscribe

Patent: 42175
Estimated Expiration: ⤷  Subscribe

Patent: 52841
Estimated Expiration: ⤷  Subscribe

Patent: 16503010
Patent: 3−(イミダゾ[1,2−b]ピリダジン−3−イルエチニル)−4−メチル−N−{4−[(4−メチルピペラジン−1−イル)メチル]−3−(トリフルオロメチル)フェニル}ベンズアミドおよびその一塩酸塩の結晶形
Estimated Expiration: ⤷  Subscribe

Patent: 18168191
Patent: 3−(イミダゾ[1,2−b]ピリダジン−3−イルエチニル)−4−メチル−N−{4−[(4−メチルピペラジン−1−イル)メチル]−3−(トリフルオロメチル)フェニル}ベンズアミドおよびその一塩酸塩の結晶形 (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONOHYDROCHLORIDE SALTS)
Estimated Expiration: ⤷  Subscribe

Patent: 22037122
Patent: 3-(イミダゾ[1,2-b]ピリダジン-3-イルエチニル)-4-メチル-N-{4-[(4-メチルピペラジン-1-イル)メチル]-3-(トリフルオロメチル)フェニル}ベンズアミドおよびその一塩酸塩の結晶形
Estimated Expiration: ⤷  Subscribe

Patent: 23179498
Patent: 3-(イミダゾ[1,2-b]ピリダジン-3-イルエチニル)-4-メチル-N-{4-[(4-メチルピペラジン-1-イル)メチル]-3-(トリフルオロメチル)フェニル}ベンズアミドおよびその一塩酸塩の結晶形 (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONOHYDROCHLORIDE SALTS)
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 9147
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3-ILETINIL)-4-ME TIL-N-(4-[ (4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL) FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 15007578
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3-ILETINIL)-4-ME TIL-N-(4-[ (4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL) FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002253
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002254
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002255
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002256
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002257
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002258
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002259
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002261
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

Patent: 21002264
Patent: FORMAS CRISTALINAS DE 3-(IMIDAZO[1,2-B] PIRIDAZIN-3- ILETINIL)-4-METIL-N-(4-[(4-METILPIPERAZIN-1-IL) METIL]-3-(TRIFLUOROMETIL)FENIL) BENZAMIDA Y SU SAL DE MONOCLORHIDRATO. (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-M ETHYL-N-(4-[(4-METHYLPIPERAZIN-1-YL) METHYL]-3-(TRIFLUOROMETHYL)P HENYL)BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT.)
Estimated Expiration: ⤷  Subscribe

New Zealand

Patent: 9648
Patent: Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ICLUSIG around the world.

Country Patent Number Title Estimated Expiration
Slovenia 1973545 ⤷  Subscribe
European Patent Office 2495016 Composants hétéroaromatiques bicycliques (Bicyclic Heteroaryl Compounds) ⤷  Subscribe
Canada 3167093 FORME CRISTALLINE C DU MONOCHLORHYDRATE DE BENZAMIDE A FONCTION 3-(IMIDAZO[1,2-B]PYRIDAZINE-3-YLETHYNYL)-4-METHYLE-N-{4-[(4-METHYLPIPERAZINE-1-YL)METHYLE)3(TRIFLUOROMETHYLE)PHENYLE} (CRYSTALLINE FORM C OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL)-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE) ⤷  Subscribe
Eurasian Patent Organization 200870514 АЦЕТИЛЕНОВЫЕ ГЕТЕРОАРИЛЬНЫЕ СОЕДИНЕНИЯ ⤷  Subscribe
Canada 3022250 FORMES CRISTALLINES DE 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZ IN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE (CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE) ⤷  Subscribe
Spain 2555515 ⤷  Subscribe
Canada 2634923 COMPOSES HETEROARYLES BICYCLIQUES (BICYCLIC HETEROARYL COMPOUNDS) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ICLUSIG

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1973545 72/2013 Austria ⤷  Subscribe PRODUCT NAME: PONATINIB; REGISTRATION NO/DATE: EU/1/13/839 20130701
1973545 490 Finland ⤷  Subscribe
1973545 92327 Luxembourg ⤷  Subscribe PRODUCT NAME: PONATINIB SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE
1973545 122013000152 Germany ⤷  Subscribe PRODUCT NAME: PONATINIB "BENZAMID, 3-(2-IMIDAZO(1,2-B)PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYL-1-PIPERAZINYL)METHYL)-3-(TRIFLUORMETHYL)PHENYL)"; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
1973545 SPC/GB13/077 United Kingdom ⤷  Subscribe PRODUCT NAME: PONATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE OR HYDRATE THEREOF; REGISTERED: UK EU/1/13/839/001 20130703; UK EU/1/13/839/002 20130703; UK EU/1/13/839/003 20130703; UK EU/1/13/839/004 20130703
1973545 13C0069 France ⤷  Subscribe PRODUCT NAME: PONATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, SOLVATE OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
1973545 C300631 Netherlands ⤷  Subscribe PRODUCT NAME: PONATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, SOLVAAT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

ICLUSIG Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for ICLUSIG

Introduction to ICLUSIG

ICLUSIG, a targeted therapy developed by Takeda Pharmaceuticals (originally by Ariad Pharmaceuticals), has revolutionized the treatment of certain types of cancer, particularly chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here, we delve into the market dynamics and financial trajectory of ICLUSIG, highlighting its growth, market impact, and future prospects.

Growing Demand for Targeted Therapies

The global cancer treatment market has seen significant growth driven by rising cancer incidence, innovations in oncology therapies, and the increasing availability of targeted treatments. ICLUSIG is at the forefront of this trend, benefiting from the surge in demand for targeted therapies that specifically aim at cancer cells, minimizing damage to healthy tissues[1].

Market Expansion and Global Reach

ICLUSIG's market is expanding rapidly, particularly in developed markets such as the U.S., Europe, and Japan, where advanced healthcare infrastructure and high healthcare spending facilitate the adoption of innovative treatments. The U.S. alone accounts for a significant share of the global oncology market, and ICLUSIG has been recognized as a valuable option for resistant leukemia cases[1].

In addition to developed markets, ICLUSIG's adoption is also on the rise in emerging markets, including the Asia-Pacific and Latin America regions. As healthcare systems in these regions improve and access to advanced cancer treatments becomes more feasible, the market for ICLUSIG is expected to expand further[1].

Research and Development

Continuous research and development (R&D) are crucial for the growth of ICLUSIG. New clinical trials are exploring the use of ICLUSIG in combination with other therapies for various cancers, including solid tumors and non-Hodgkin lymphoma. If successful, these trials could open up entirely new markets for the drug, driving demand even further[1].

Financial Performance

Revenue Growth

The financial performance of ICLUSIG has been robust. In 2018, GAAP net product revenues from ICLUSIG were $80 million, compared to $67 million in the previous year. This growth trend has continued, with total revenues from oncology drugs, including ICLUSIG, contributing significantly to the overall revenue of pharmaceutical companies involved[5].

Recent Financial Trends

In the second quarter of 2024, Incyte, a company involved in the distribution and development of various oncology drugs, reported total revenues that grew 9% year-over-year, surpassing $1.0 billion. While the specific revenue from ICLUSIG was not detailed, the overall growth in oncology drug revenues indicates a positive financial trajectory for targeted therapies like ICLUSIG[2].

Costs and Expenses

The financial reports also highlight the costs associated with the development and marketing of ICLUSIG. Selling, general, and administrative expenses have increased due to factors such as acquisition-related compensation and consumer marketing activities. However, excluding these upfront costs, the expenses have remained relatively flat, indicating efficient management of operational costs[2].

Market Competition and Dynamics

Competitive Landscape

The hematology-oncology market is highly competitive, with several drugs vying for market share. ICLUSIG competes with other notable drugs like BRUKINSA®, IMBRUVICA®, VENCLEXTA®, and CALQUENCE®. Recent data shows a significant decline in the dominance of IMBRUVICA® as new drugs enter the market, with BRUKINSA® demonstrating remarkable growth and VENCLEXTA® emerging as the leading therapeutic[4].

Demographic Insights

Demographic analysis reveals that Medicare is the dominant payer for most prescriptions, and non-Hispanic Whites make up the largest percentage of the treated population. Treated patients are also more likely to be male, aligning with higher incidence rates of blood cancers among these demographics[4].

Partnerships and Collaborations

Partnerships between pharmaceutical companies and healthcare providers are crucial for accelerating the development and approval of new cancer drugs. Collaborations involving ICLUSIG could help bring new treatment combinations to market faster, benefiting both patients and investors. Mergers and acquisitions in the pharmaceutical industry can also lead to the expansion of a product’s market presence, potentially making ICLUSIG more accessible and affordable in emerging markets[1].

Investment Potential

Biotech investors are keenly interested in targeted cancer therapies like ICLUSIG. As healthcare systems prioritize cancer treatment, there is significant potential for companies manufacturing and distributing such drugs to see strong returns on investment. The global expansion of personalized medicine is also expected to drive long-term growth in the market for drugs like ICLUSIG[1].

Future Prospects

The future of ICLUSIG looks promising, with ongoing research into new formulations and therapeutic combinations. The drug's effectiveness and applicability are being broadened through clinical trials, which will optimize treatment outcomes as the understanding of cancer biology evolves. The market for ICLUSIG is projected to experience substantial growth between 2024 and 2032, driven by increasing demand for advanced cancer therapies and improvements in healthcare infrastructure in emerging markets[3].

Key Takeaways

  • Growing Demand: ICLUSIG benefits from the rising demand for targeted therapies in oncology.
  • Global Reach: The drug is expanding its market presence in both developed and emerging markets.
  • R&D: Continuous research and development are key to opening new markets for ICLUSIG.
  • Financial Performance: Revenue growth and efficient cost management indicate a positive financial trajectory.
  • Market Competition: ICLUSIG competes in a dynamic market with shifting clinical preferences and demographic variations.
  • Partnerships: Collaborations are essential for accelerating drug development and market expansion.
  • Investment Potential: Strong potential for returns on investment due to the growing importance of targeted therapies.

FAQs

Q: What types of cancer does ICLUSIG treat?

ICLUSIG is used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in patients who have developed resistance or intolerance to other treatments[1].

Q: Why is ICLUSIG preferred over traditional chemotherapy?

ICLUSIG is preferred because it specifically targets cancer cells, minimizing damage to healthy tissues and resulting in fewer side effects and better efficacy compared to traditional chemotherapy[1].

Q: What regions are seeing the most growth in ICLUSIG adoption?

ICLUSIG's adoption is on the rise in both developed markets like the U.S., Europe, and Japan, and in emerging markets such as the Asia-Pacific and Latin America regions[1].

Q: How does ICLUSIG compete in the hematology-oncology market?

ICLUSIG competes with other drugs like BRUKINSA®, IMBRUVICA®, VENCLEXTA®, and CALQUENCE®, with market dynamics shifting as new drugs enter the market and clinical preferences evolve[4].

Q: What are the future prospects for ICLUSIG?

The future of ICLUSIG looks promising with ongoing research, new therapeutic combinations, and projected substantial growth between 2024 and 2032 driven by increasing demand for advanced cancer therapies[3].

Sources

  1. Market Research Intellect: "Iclusig Market Size And Projection - Market Research Intellect"
  2. Incyte: "Incyte Reports 2024 Second Quarter Financial Results and Provides Business Update"
  3. Wicz: "Iclusig Market Size Insights Report 2024-2032 | 92 Pages Report"
  4. Komodo Health: "Drug Snapshot: Shifting Paradigms in Hematology-Oncology"
  5. Incyte: "Incyte Reports 2018 Fourth Quarter and Year-End Financial Results"

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.